Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fernando Bermejo

Showing results (121-130 of 133) with videos related to

Pageof 14
Sort By:
Journal of Crohn'S & Colitis|August 1, 2022
Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA RegistryDiego Casas-Deza, Luis Javier Lamuela-Calvo, Fernando Gomollón, et al.
The American Journal of Gastroenterology|January 30, 2023
Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and SafetyMaría Chaparro, Diana Acosta, Cristina Rodríguez, et al.
United European Gastroenterology Journal|December 6, 2025
Comparative Study on the Management and Outcomes of Postoperative Crohn's Disease in Older Patients: Data From the ENEIDA RegistryMíriam Mañosa, Margalida Calafat, Elena Ricart, et al.
Journal of Crohn'S & Colitis|April 16, 2021
Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA RegistryMaría Chaparro, Ana Garre, Marisa Iborra, et al.
Inflammatory Bowel Diseases|February 15, 2022
Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN StudyMaría Chaparro, Iria Baston-Rey, Estela Fernández-Salgado, et al.
Journal of Crohn'S & Colitis|May 8, 2019
Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort StudyIvan Guerra, Luis Bujanda, Jesús Castro, et al.
Journal of Clinical Medicine|August 12, 2022
Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn's Disease Patients on UstekinumabMaría Chaparro, Iria Baston-Rey, Estela Fernández Salgado, et al.
Alimentary Pharmacology & Therapeutics|August 8, 2025
Frequency and Effectiveness of Dose Escalation and De-Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW-IBD Study of ENEIDACristina Rubín de Célix, Elena Ricart, M Dolores Martín-Arranz, et al.
Alimentary Pharmacology & Therapeutics|June 29, 2024
Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registryRocío Ferreiro-Iglesias, Sol Porto Silva, Sandra Marín, et al.
Alimentary Pharmacology & Therapeutics|September 17, 2024
Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES studyMaría Chaparro, Sandra Hermida, Diana Acosta, et al.
Pageof 14

Showing results (121-130 of 133) with videos related to

Sort By:
Pageof 14
Journal of Crohn'S & Colitis|August 1, 2022
Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA RegistryDiego Casas-Deza, Luis Javier Lamuela-Calvo, Fernando Gomollón, et al.
The American Journal of Gastroenterology|January 30, 2023
Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and SafetyMaría Chaparro, Diana Acosta, Cristina Rodríguez, et al.
United European Gastroenterology Journal|December 6, 2025
Comparative Study on the Management and Outcomes of Postoperative Crohn's Disease in Older Patients: Data From the ENEIDA RegistryMíriam Mañosa, Margalida Calafat, Elena Ricart, et al.
Journal of Crohn'S & Colitis|April 16, 2021
Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA RegistryMaría Chaparro, Ana Garre, Marisa Iborra, et al.
Inflammatory Bowel Diseases|February 15, 2022
Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN StudyMaría Chaparro, Iria Baston-Rey, Estela Fernández-Salgado, et al.
Journal of Crohn'S & Colitis|May 8, 2019
Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort StudyIvan Guerra, Luis Bujanda, Jesús Castro, et al.
Journal of Clinical Medicine|August 12, 2022
Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn's Disease Patients on UstekinumabMaría Chaparro, Iria Baston-Rey, Estela Fernández Salgado, et al.
Alimentary Pharmacology & Therapeutics|August 8, 2025
Frequency and Effectiveness of Dose Escalation and De-Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW-IBD Study of ENEIDACristina Rubín de Célix, Elena Ricart, M Dolores Martín-Arranz, et al.
Alimentary Pharmacology & Therapeutics|June 29, 2024
Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registryRocío Ferreiro-Iglesias, Sol Porto Silva, Sandra Marín, et al.
Alimentary Pharmacology & Therapeutics|September 17, 2024
Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES studyMaría Chaparro, Sandra Hermida, Diana Acosta, et al.
Pageof 14